Arenas strategy was to go after the low-hanging fruit. Jack felt that Belviq would be a great drug after watching the success of fen-phen before and the issues. They would use the cash flow from Belviq sales to further the pipeline and the GPCR Technologies. As it turned out the FDA required a much longer more in-depth studies for Belviq we had a complete response letter that we had to deal with from the FDA which delayed this a year and then we had another 11 months taken away from the classification by the DEA. So we have had our fair share of issues, that is why the delay in bringing the pipeline forward. Is your get one drug approved gives the cash flow from that one drug to bring three or four other drugs forward.
Well we will have to agree to disagree. Belviq the drug is not a failure, Eisai is the failure. Too small of a marketing company and has no clue how to Market in the United States. And we both know the pipeline is not 20 years old.
The company did not have an approved drug and did not have the pipeline and GPCR technology we do. Not an apples to apples comparison. I read all of their drugs were in comparability phase of studies.
OVERVIEW NEWS KEY DEVELOPMENTS PEOPLE CHARTS FINANCIALS ANALYSTS RESEARCH PULSE
EPRSQ.PK on OTC Markets Group
22 Sep 2016
Change (% chg)
EPIRUS Biopharmaceuticals, Inc. (Epirus), incorporated on March 28, 2000, is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. The Company's segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company focuses on approximately five biosimilar product candidates in the autoimmune and inflammation areas, including BOW015, a biosimilar version of Remicade (infliximab); BOW050 a biosimilar version of Humira (adalimumab); BOW070, a biosimilar version of Actemra (tocilizumab); BOW090, a biosimilar version of STELARA (ustekinumab), and BOW100, a biosimilar version of SIMPONI (golimumab). The Company also focuses on BOW080, a biosimilar version of Soliris (eculizumab).
The Company's lead product candidate is BOW015 (infliximab, reference biologic Remicade), a monoclonal antibody against tumor necrosis factor alpha (TNF-a). BOW015 is intended for the treatment of inflammatory diseases, including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, psoriatic arthritis and psoriasis. The Company has conducted bioanalytical and physicochemical comparisons of BOW015 to Remicade.
belive they can manage with the current cash on hand and projected to come in, through the end of all the Phase 2 study results. So you either belive them or you don't, and if you don't, why do you think they are not being honest? What historical evidence do you have that they can not be trusted? They have major stock options at these prices, does them no good to tank the stock down from here.
If the stock gets way ahead of its self does that create an opportunity to raise capital, yes, however I would argue that both Kevin and Amit know this company has a credibility issue with investors and Wall Street so they will try as hard as they can to hit dead lines and to do as they has guided, to build confidence in the new management.
Do you consider testing the low a sell. off or just part of a reversal and break out pattern. I for one do not believe a sell off is coming. Anyone was going to sell has sold and many that are still here know what they own so Amy pull back will be met with more buying.
Arena has nothing to sell in Beacon, so no they will not be selling anything.
Spinning off Been was a great call and the deal structure was a major win win. Arena gave nothing away and lost nothing.
What does that have to do with my post? Sales and revenue are the life blood of every company. Growing companies and research companies burn cash while building a market and a presence. We built a product and got it to market, Belviq is approved in 3 counties and moving towards approval in a couple more. Belviq XR is now approved for US. If the drug is not selling, that is not a reflection today on Arena or Belviq. It is directly tied to Doctors willingness to script and Eisai's ability to market the drug. If you want to bash someone, go bash Eisai who has single handedly wiped out Arena shareholder value.
Not according to Eisai Investor Relations, they will be moving forward as disclosed.
Then sell and move on, or put your money where your mouth is and short.. Baseless bashing and name calling is childish and serves no purpose. Your post brings nothing of value to this investment board.
Only way to enrich themselves is to get the stock price up over their stock option 3xercise price. Do you know what that price is for Amit and Kevin? You might want to start there with your DD.
What is the 'Altman Z-Score'
The Altman Z-score is the output of a credit-strength test that gauges a publicly traded manufacturing company's likelihood of bankruptcy. The Altman Z-score is based on five financial ratios that can be calculated from data found on a company's annual 10K report. It uses profitability, leverage, liquidity, solvency and activity to predict whether a company has a high degree of probability of being insolvent.
Busted like I said below, not for Biotechnology move on.
That scoring is not designed to score Bio Tech companies with Binary events. But you already know this.
It is a non issue. We were granted the patents, we own the technology for while.
And the 40 million a year in top line revenue helps a little as well.
I don't think that will change any plans, sales are revenue and that is the primary goal for all for profit organizations.
Nope, the patent was granted giving them patent protection. They will prove the patent and we will find out who is playing games soon enough.